Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 μg/ml in Korea

Hong Bin Kim, Yeong Seon Lee, Bong Su Kim, Jeong Ok Cha, Sung Uk Kwon, Hee Joo Lee, Jin Tae Suh, Insoo Rheem, Jeong Man Kim, Bo Moon Shin, Mi Na Kim, Kyungwon Lee, Chang Seop Lee, Eui Chong Kim, Myoung Don Oh, Kang Won Choe

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In addition to vancomycin-intermediate Staphylococcus aureus (VISA), S. aureus with a vancomycin MIC of 4 μg/ml has been reported to be the cause of therapeutic failure. This study was designed to determine the prevalence of methicillin-resistant S. aureus (MRSA) with a vancomycin MIC of 4 μg/ml and to clarify the clinical characteristics of infections caused by these isolates. During the 8-week period from April to May, 2001, 27 hospitals participated in a nationwide surveillance program for VISA and vancomycin-resistant S. aureus (VRSA) in Korea. After screening on brain-heart infusion agar containing 4 μg/ml of vancomycin as previously described, 100 isolates with confluent growth were tested. The medical records of the patients involved were reviewed. Even though VISA or VRSA was not detected among 3,756 MRSA isolates, 18 (0.5%) had a vancomycin MIC of 4 μg/ml The infections in 12 of these patients, excluding 5 that were colonized, were 8 chronic osteomyelitis, 1 surgical site infection, 1 pneumonia, 1 intra-abdominal infection, and 1 catheter-related infection. Although 11 cases were exposed to glycopeptides for a long time (median 56 days), the site of infection became culture-negative in only 1 case. Two patients died of their S. aureus infections. MRSA with a vancomycin MIC of 4 μg/ml was rare. Chronic osteomyelitis was the most common type of infection, and prolonged exposure to glycopeptides was associated with reduced susceptibility to vancomycin.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalMicrobial Drug Resistance
Volume12
Issue number1
DOIs
Publication statusPublished - 2006 Mar 1

Fingerprint

Vancomycin
Korea
Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus
Infection
Glycopeptides
Osteomyelitis
Intraabdominal Infections
Surgical Wound Infection
Catheter-Related Infections
Agar
Medical Records
Pneumonia

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Pharmacology
  • Microbiology (medical)

Cite this

Kim, H. B., Lee, Y. S., Kim, B. S., Cha, J. O., Kwon, S. U., Lee, H. J., ... Choe, K. W. (2006). Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 μg/ml in Korea. Microbial Drug Resistance, 12(1), 33-38. https://doi.org/10.1089/mdr.2006.12.33
Kim, Hong Bin ; Lee, Yeong Seon ; Kim, Bong Su ; Cha, Jeong Ok ; Kwon, Sung Uk ; Lee, Hee Joo ; Suh, Jin Tae ; Rheem, Insoo ; Kim, Jeong Man ; Shin, Bo Moon ; Kim, Mi Na ; Lee, Kyungwon ; Lee, Chang Seop ; Kim, Eui Chong ; Oh, Myoung Don ; Choe, Kang Won. / Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 μg/ml in Korea. In: Microbial Drug Resistance. 2006 ; Vol. 12, No. 1. pp. 33-38.
@article{f32fca15b01c4028b33a8fab78f8d684,
title = "Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 μg/ml in Korea",
abstract = "In addition to vancomycin-intermediate Staphylococcus aureus (VISA), S. aureus with a vancomycin MIC of 4 μg/ml has been reported to be the cause of therapeutic failure. This study was designed to determine the prevalence of methicillin-resistant S. aureus (MRSA) with a vancomycin MIC of 4 μg/ml and to clarify the clinical characteristics of infections caused by these isolates. During the 8-week period from April to May, 2001, 27 hospitals participated in a nationwide surveillance program for VISA and vancomycin-resistant S. aureus (VRSA) in Korea. After screening on brain-heart infusion agar containing 4 μg/ml of vancomycin as previously described, 100 isolates with confluent growth were tested. The medical records of the patients involved were reviewed. Even though VISA or VRSA was not detected among 3,756 MRSA isolates, 18 (0.5{\%}) had a vancomycin MIC of 4 μg/ml The infections in 12 of these patients, excluding 5 that were colonized, were 8 chronic osteomyelitis, 1 surgical site infection, 1 pneumonia, 1 intra-abdominal infection, and 1 catheter-related infection. Although 11 cases were exposed to glycopeptides for a long time (median 56 days), the site of infection became culture-negative in only 1 case. Two patients died of their S. aureus infections. MRSA with a vancomycin MIC of 4 μg/ml was rare. Chronic osteomyelitis was the most common type of infection, and prolonged exposure to glycopeptides was associated with reduced susceptibility to vancomycin.",
author = "Kim, {Hong Bin} and Lee, {Yeong Seon} and Kim, {Bong Su} and Cha, {Jeong Ok} and Kwon, {Sung Uk} and Lee, {Hee Joo} and Suh, {Jin Tae} and Insoo Rheem and Kim, {Jeong Man} and Shin, {Bo Moon} and Kim, {Mi Na} and Kyungwon Lee and Lee, {Chang Seop} and Kim, {Eui Chong} and Oh, {Myoung Don} and Choe, {Kang Won}",
year = "2006",
month = "3",
day = "1",
doi = "10.1089/mdr.2006.12.33",
language = "English",
volume = "12",
pages = "33--38",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

Kim, HB, Lee, YS, Kim, BS, Cha, JO, Kwon, SU, Lee, HJ, Suh, JT, Rheem, I, Kim, JM, Shin, BM, Kim, MN, Lee, K, Lee, CS, Kim, EC, Oh, MD & Choe, KW 2006, 'Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 μg/ml in Korea', Microbial Drug Resistance, vol. 12, no. 1, pp. 33-38. https://doi.org/10.1089/mdr.2006.12.33

Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 μg/ml in Korea. / Kim, Hong Bin; Lee, Yeong Seon; Kim, Bong Su; Cha, Jeong Ok; Kwon, Sung Uk; Lee, Hee Joo; Suh, Jin Tae; Rheem, Insoo; Kim, Jeong Man; Shin, Bo Moon; Kim, Mi Na; Lee, Kyungwon; Lee, Chang Seop; Kim, Eui Chong; Oh, Myoung Don; Choe, Kang Won.

In: Microbial Drug Resistance, Vol. 12, No. 1, 01.03.2006, p. 33-38.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 μg/ml in Korea

AU - Kim, Hong Bin

AU - Lee, Yeong Seon

AU - Kim, Bong Su

AU - Cha, Jeong Ok

AU - Kwon, Sung Uk

AU - Lee, Hee Joo

AU - Suh, Jin Tae

AU - Rheem, Insoo

AU - Kim, Jeong Man

AU - Shin, Bo Moon

AU - Kim, Mi Na

AU - Lee, Kyungwon

AU - Lee, Chang Seop

AU - Kim, Eui Chong

AU - Oh, Myoung Don

AU - Choe, Kang Won

PY - 2006/3/1

Y1 - 2006/3/1

N2 - In addition to vancomycin-intermediate Staphylococcus aureus (VISA), S. aureus with a vancomycin MIC of 4 μg/ml has been reported to be the cause of therapeutic failure. This study was designed to determine the prevalence of methicillin-resistant S. aureus (MRSA) with a vancomycin MIC of 4 μg/ml and to clarify the clinical characteristics of infections caused by these isolates. During the 8-week period from April to May, 2001, 27 hospitals participated in a nationwide surveillance program for VISA and vancomycin-resistant S. aureus (VRSA) in Korea. After screening on brain-heart infusion agar containing 4 μg/ml of vancomycin as previously described, 100 isolates with confluent growth were tested. The medical records of the patients involved were reviewed. Even though VISA or VRSA was not detected among 3,756 MRSA isolates, 18 (0.5%) had a vancomycin MIC of 4 μg/ml The infections in 12 of these patients, excluding 5 that were colonized, were 8 chronic osteomyelitis, 1 surgical site infection, 1 pneumonia, 1 intra-abdominal infection, and 1 catheter-related infection. Although 11 cases were exposed to glycopeptides for a long time (median 56 days), the site of infection became culture-negative in only 1 case. Two patients died of their S. aureus infections. MRSA with a vancomycin MIC of 4 μg/ml was rare. Chronic osteomyelitis was the most common type of infection, and prolonged exposure to glycopeptides was associated with reduced susceptibility to vancomycin.

AB - In addition to vancomycin-intermediate Staphylococcus aureus (VISA), S. aureus with a vancomycin MIC of 4 μg/ml has been reported to be the cause of therapeutic failure. This study was designed to determine the prevalence of methicillin-resistant S. aureus (MRSA) with a vancomycin MIC of 4 μg/ml and to clarify the clinical characteristics of infections caused by these isolates. During the 8-week period from April to May, 2001, 27 hospitals participated in a nationwide surveillance program for VISA and vancomycin-resistant S. aureus (VRSA) in Korea. After screening on brain-heart infusion agar containing 4 μg/ml of vancomycin as previously described, 100 isolates with confluent growth were tested. The medical records of the patients involved were reviewed. Even though VISA or VRSA was not detected among 3,756 MRSA isolates, 18 (0.5%) had a vancomycin MIC of 4 μg/ml The infections in 12 of these patients, excluding 5 that were colonized, were 8 chronic osteomyelitis, 1 surgical site infection, 1 pneumonia, 1 intra-abdominal infection, and 1 catheter-related infection. Although 11 cases were exposed to glycopeptides for a long time (median 56 days), the site of infection became culture-negative in only 1 case. Two patients died of their S. aureus infections. MRSA with a vancomycin MIC of 4 μg/ml was rare. Chronic osteomyelitis was the most common type of infection, and prolonged exposure to glycopeptides was associated with reduced susceptibility to vancomycin.

UR - http://www.scopus.com/inward/record.url?scp=33646021273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646021273&partnerID=8YFLogxK

U2 - 10.1089/mdr.2006.12.33

DO - 10.1089/mdr.2006.12.33

M3 - Article

C2 - 16584306

AN - SCOPUS:33646021273

VL - 12

SP - 33

EP - 38

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 1

ER -